Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319923 | 0.89 | TP53 (0.39) | TACR1MMP2MMP9MMP8CTSL | |
| SCHEMBL6325996 | 0.87 | MMP2 (0.38) | TACR1MMP2MMP9MMP8CTSL | |
| SCHEMBL6319699 | 0.83 | KLKB1 (0.43) | TACR1MMP2MMP9MMP8TP53 | |
| SCHEMBL6319686 | 0.82 | MMP2 (0.44) | TACR1MMP2MMP9MMP8CTSL | |
| SCHEMBL6318941 | 0.82 | TP53 (0.37) | TACR1MMP2MMP9MMP8TP53 | |
| SCHEMBL6319162 | 0.82 | TP53 (0.37) | TACR1MMP2MMP9MMP8TP53 | |
| SCHEMBL6325830 | 0.81 | CTSL (0.48) | TACR1MMP2MMP9MMP8CTSL | |
| SCHEMBL6319176 | 0.80 | KLKB1 (0.37) | TACR1MMP2MMP9MMP8OPRD1 | |
| SCHEMBL6319016 | 0.79 | GHSR (0.49) | MMP2MMP9MMP8CTSLCTSS | |
| SCHEMBL6324008 | 0.79 | CTSL (0.39) | TACR1MMP2MMP9MMP8CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | TACR1 232/4885MMP2 2624/4885MMP9 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.